WELCOME! Identifying and Managing Neonatal Abstinence Syndrome. ALICE ORDEAN MD, CCFP, MHSC, FCFP, ABAM Dip. Wednesday, March 11, pm to 1pm
|
|
- Georgina Hamilton
- 7 years ago
- Views:
Transcription
1 WELCOME! Identifying and Managing Neonatal Abstinence Syndrome ALICE ORDEAN MD, CCFP, MHSC, FCFP, ABAM Dip. Wednesday, March 11, pm to 1pm
2 Identifying and Managing Neonatal Abstinence Syndrome ALICE ORDEAN MD, CCFP, MHSC, FCFP, ABAM Dip. Medical Director, T-CUP, St. Joseph s Health Centre Associate Professor, DFCM, University of Toronto March 11, 2015
3 Outline Prevalence of perinatal opioid use and NAS Approach to comprehensive management of prenatal opioid use disorders Approach to identification and management of NAS Supportive measures Pharmacotherapy
4 Prevalence of Opioid Use Disorder in General Population Annual prescribing of opioids increased from 1991 to 2007 from 458 to 591 per 1000 individuals (increase of 29%) Treatment for prescription opioids in addiction services increased from 10.6% in 2005/6 to 18.6% in 2010/11 OPICAN study, 2005 demonstrated that type of illicit opioid use varies by province: prescription opioid misuse more common in Toronto
5 Prevalence of Opioid Use Disorder in General Population (2) CADUMS, 2011 (Canadian Alcohol and Other Drug use Monitoring Survey) revealed that 1 in 6 Canadians reported past year prescription opioid use abuse rates ~5% CAMH Monitor, 2013 found that 22% of Ontario adults reported past year use of prescription opioid pain relievers, ~3% use for non-medical purposes
6 Prevalence of Opioid Use Disorder during Pregnancy Prevalence of opioid use during pregnancy varies by population studied (geographical location) & method for detection (self-report vs. toxicology) Availability of perinatal Canadian data limited 2010 U.S. National Survey on Drug Use and Health: 4-5% of pregnant women reported illicit drug use in past 30 days, 0.1% heroin use and 1-2 % non-medical use of prescription opioids
7 Rates of neonatal abstinence syndrome (NAS) Data source Canadian Institute for Health Information (CIHI)
8 NAS Bed Utilization: Ontario Year Number of infants with NAS diagnosis Average length of stay (days) Beds per day utilized across province for NAS Comparison to healthy term newborn average LOS in 2004 was 1.4 days Data source - Canadian Institute for Health Information (CIHI)
9 NAS Bed Utilization: Summary ~3 % of neonatal beds occupied by infants diagnosed with NAS Average length of stay (LOS) for these neonates is 15 days versus 1.4 days for a term newborn Range of LOS highly variable, >42 days in some hospitals Some centers with interest/need/expertise can have 10-20% of newborns in special care nursery (SCN) with diagnosis of NAS
10 Polysubstance Use Pregnant women with opioid use disorder also report oregular alcohol and cigarette smoking ocomorbid drug use: o Benzodiazepines o Cocaine o Marijuana
11 High incidence of concomitant illicit drug use during pregnancy Canadian national cohort of 102 opioid-dependent pregnancies, receiving care at 3 integrated care programs in Vancouver, Toronto and Montreal Demographics: 29.7 years, 64% white, 50% single, 61% on social assistance 50% on methadone prior to conception, other half initiated during pregnancy at mean of 21 weeks gestational age Ordean et al. Can Fam Phys 2013
12 High incidence of concomitant illicit drug use during pregnancy(2) At first visit, pregnant women reported 46% heroin use, 27% prescription opioid use Geographical differences: prescription opioid use more common in Toronto (48%), heroin use more frequent in Vancouver (80%) and Montreal (50%) Polysubstance use: 87% nicotine, 44% cocaine, 25% alcohol, marijuana, benzodiazepines By delivery, significant reductions in heroin (16%) and prescription opioids (10%), cocaine (19%), marijuana (7%) and alcohol (5%) use
13 Opioid Use Disorder DSM V Criteria Problematic pattern of opioid use leading to clinically significant impairment 2 or more of the following within 12 months: 1. Opioids taken in larger amounts or over longer period than intended 2. Persistent desire to cut down 3. Great deal of time spent in activities to obtain, use or recover from its effects 4. Craving to use 5. Failure to fulfill major role obligations work, home
14 Opioid Use Disorder DSM V Criteria (2) 6. Continued use despite social or interpersonal problems 7. Important social, occupational or recreational activities given up 8. Recurrent opioid use in physically hazardous situations 9. Continued use despite physical or psychological problems 10. Tolerance 11. Withdrawal
15 Risks of Antenatal Opioid Use Consequences of antenatal opioid use due to repeated cycles of intoxication and withdrawal Prescription opioid misuse associated with: Intrauterine growth restriction Increased risk of spontaneous abortion Increased risk of prematurity and low birth weight leading to increased neonatal morbidity & mortality rates Increased risk of SIDS (sudden infant death syndrome)
16 Risks of Antenatal Opioid Use (2) Infants exposed to any regular use of opioids such as methadone, morphine, codeine, oxycodone and heroin in utero develop a physical dependence on these substances As a result, infant is at risk of developing withdrawal symptoms and signs after birth when no longer exposed to any opioid Neonatal opioid withdrawal can occur in 55-94% of infants exposed to opioids in utero
17 Approach to Care for Opioid Use Disorder in Pregnancy Engagement and retention in care Opioid withdrawal management Opioid agonist treatment (OAT) during pregnancy o Methadone: maintenance vs. detoxification o Buprenorphine o Morphine (slow-release) Comprehensive care including antenatal care and social services
18 Pregnancy: Window of Opportunity Pregnancy represents a window of opportunity, a teachable moment when women have an increased perceived risk of harm Pregnant women are more likely to access long-term substance abuse treatment programs (e.g. methadone maintenance programs) and more likely to re-access detoxification programs due to interest in stopping drug use for child s health and fear of child protection services
19 Integrated Care Program Comprehensive programs that combine pregnancy care with substance use treatment in one location - one-stop shop model Meta-analysis found that women in integrated programs had improved neonatal outcomes (higher birth weight, fewer birth complications) and maternal outcomes (fewer positive drug screening, more prenatal visits & fewer preterm births) Milligan et al., Addiction Research and Theory, 2011.
20 Opioid Agonist Treatment Current standard of care for opioid use disorder in pregnancy is methadone maintenance treatment (MMT) Due to limited experience with use of buprenorphine during pregnancy, its use can be considered after discussion of benefits and risks of buprenorphine Structured opioid-prescribing (eg. use of other sustained-release opioid preparations) can be last option if no access to methadone or buprenorphine
21 Rationale for OAT Substitute for heroin or prescription opioids Accumulates in tissues with repeated daily oral administration Relieves opioid withdrawal and reduces cravings for opioids by blocking euphoric effects of self-administered illicit opioids (cross-tolerance) leading to reduced illicit drug use Once stabilized on a dose, subsequent doses should not cause sedation, analgesia, or euphoria Allows normal function to perform mental & physical tasks
22 Rationale for OAT in Pregnancy Decreased complications due to repeated cycles of intoxication and withdrawal (e.g., miscarriage, premature labour, fetal death) Reduced rates of prematurity, low birth weight & infant mortality Improved prenatal care & nutrition Decreased risk of Hepatitis C & HIV (since reduces needle & paraphernalia sharing
23 What is methadone? Oral synthetic opioid Effects similar to morphine Dispensed as a liquid solution made by dissolving methadone in orange drink (to prevent injection) Well-absorbed from gastrointestinal tract Peak effect at 2-4 hours Long duration of action: hours
24 Methadone Side-Effects Constipation* Sweating* Weight gain Decreased libido, fatigue* Decreased level of consciousness, respiratory depression with excessive doses Neonatal withdrawal * increased during pregnancy!
25 MMT Components Frequency of MD visits depends on stability Each visit includes review of dose, relapse prevention counselling, urine drug testing MD requires exemption to prescribe MMT Visits to pharmacy depend on number of drinks & carries Treatment contract also required which indicates voluntary participation in MMT, rules and expectations for use of methadone
26 MMT Dose Adjustment Women who develop symptoms during pregnancy, will require dose adjustment: increased methadone dose or decreased dosing interval (i.e. split-dosing) to maintain therapeutic methadone plasma concentrations Pregnant women should be offered split-dosing when single dose treatment produces maternal withdrawal (especially towards end of dosing interval) or abnormal fetal activity patterns Dose may need to be decreased after delivery
27 What is Buprenorphine? Sublingual tablet, approved for use in Canada for nonpregnant population in 2007 Rapid absorption when placed under tongue Peak effect in 1-4 hrs, long half-life hrs Ceiling effect safer in overdose Buprenorphine showed little physical dependence & milder withdrawal with abrupt discontinuation of medication in contrast to methadone
28 Rationale for Buprenorphine during Pregnancy Partial mu-opioid agonist - relieves withdrawal symptoms & suppresses opioid cravings Numerous randomized controlled trials documented that buprenorphine produces opioid-like effects equivalent to methadone reduces opioid use (i.e. effective opioid substitution therapy) Early promising results that newborns exposed to buprenorphine had shorter & milder neonatal abstinence syndrome than with methadone reduced health care costs & beneficial for families
29 Components of Buprenorphine Maintenance No restrictions all pharmacies may dispense & all physicians can prescribe buprenorphine Recommended completion of prescribing course, oneday clinical observation of an opioid-dependency practice and ongoing continuing medical education Urine drug testing at each visit, no specific schedule recommended Pharmacy visits depends on stability can grant take home doses on faster schedule
30 BMT Dosing Adjustments Titrate dose of buprenorphine until other opioid use and cravings discontinued Buprenorphine dose may need to be adjusted during pregnancy to maintain therapeutic levels, as with methadone PROMISE trial showed increase in buprenorphine dose required during last trimester of pregnancy Dose may need to be reduced postpartum
31 MOTHER Study: NAS after Methadone vs. Buprenorphine Double-blind, double-dummy randomized controlled trial 8 sites: USA, Canada(St. Joseph s Health Centre, Toronto), and Austria 175 pregnant women with opioid dependence assigned to buprenorphine (n=86) vs. methadone (n=89) No significant between group differences including substance-use characteristics
32 NAS after Methadone vs. Buprenorphine Exposure (2) 16/89 (18%) women in MMT and 28/86 (33%) women in buprenorphine group discontinued treatment Dissatisfaction with study medication was reason for discontinuation by 71% of buprenorphine vs. 13% of methadone group Doses at study discontinuation: 87mg for methadone, 14mg for buprenorphine
33 NAS after Methadone vs. Buprenorphine Exposure (3) Percentage of neonates requiring treatment for withdrawal did not differ between groups Neonates exposed to buprenorphine required 89% less morphine, spent 43% less time in hospital (10 vs days) & 58% (4.1 vs. 9.9 days) less time in hospital receiving medication for NAS Conclusion: rates of NAS among infants exposed to buprenorphine and methadone are not significantly different but buprenorphine resulted in clinically less severe NAS
34 NAS and OAT dosing Meta-analysis & systematic review (Cleary et al. 2010) concluded that severity of NAS not related to maternal methadone dose MOTHER study sub-analysis also replicated above finding and further demonstrated that maternal buprenorphine dose was not related to NAS severity, duration of treatment for NAS or length of hospital stay
35 Neonatal Abstinence Syndrome (NAS) Clinical presentation Most significant risk of any regular, daily opioid use during pregnancy is neonatal abstinence syndrome characterized by: o o o Central nervous system hyperirritability (eg. Increased muscle tone, tremors, high-pitched cry) Gastrointestinal dysfunction (eg. Poor feeding, regurgitation, loose stools, poor weight gain) Metabolic, vasomotor & respiratory disturbances (eg. recurrent sneezing & yawning, temperature instability) Onset of symptoms and signs depends on half-life of opioid used
36 NAS Severity Several variables can affect severity Nicotine exposure: number of cigarettes smoked 24 hours prior to delivery & heavy smoking associated with higher cumulative Finnegan score, longer hospital stay Psychiatric medications: antidepressants and antipsychotics associated with longer duration of NAS treatment
37 NAS Complicated by Polydrug Use Neonatal symptoms more severe with polydrug exposure especially combinations of opioids and benzodiazepines Wachman et al. demonstrated that maternal use of methadone and psychiatric medications (including SSRIs, benzodiazepines and others) increased average length of stay from 22.9 days to 26.7, 29.1 and 28.0 days respectively Wachman et al. J Addict Med, 2011.
38 NAS Premature vs. Term Infants Premature infants tend to exhibit less severe NAS than term infants Term infants have longer length of treatment, higher morphine doses for NAS treatment and as a result, longer length of stay Possible explanations for less severe NAS among preterm infants: NAS withdrawal tools designed for term infants, immature development of central nervous system, reduced total exposure to opioids and reduced placental transfer rate
39 NAS Differential Diagnosis NAS needs to be differentiated from other conditions Possible medical causes of clinical symptoms & signs need to be ruled out including: sepsis, hyperviscosity syndromes hypoglycemia, hypocalcemia hyperthyroidism intracranial hemorrhage rule out alcohol and benzodiazepine exposure
40 NAS Antenatal Care Recommendations Pregnant women should be educated antenatally about neonatal withdrawal if participating in opiate substitution programs (methadone or buprenorphine) or using other opioids on a regular basis Local variations may dictate location of infant for monitoring eg. rooming-in vs. special care nursery/neonatal intensive care unit (NICU)
41 NAS Antenatal Care Recommendations (2) The substance-using woman and her partner/family should be prepared and educated in advance for their baby s hospital experience and management of NAS. Every substance using woman should receive written materials explaining NAS, hospital stay expectations, role of the parent, and resource contacts, including the healthcare team.
42 NAS Assessment Various screening tools available for neonatal drugwithdrawal scoring Finnegan neonatal abstinence scoring system Lipsitz neonatal drug-withdrawal scoring system Ostrea tool Neonatal withdrawal inventory Neonatal narcotic withdrawal index Modified Finnegan scoring system most commonly used and best validated tool
43 NAS Assessment (2) For all opioid-exposed infants, an objective NAS scoring tool recommended: to assess severity of withdrawal symptoms and signs to determine initiation of pharmacologic treatment Scoring initiated within hours of life (every 2-4 hours) and continued depending on half-life of opioid for duration of treatment & weaning 72 hours (for short half-life) 120 hours (for longer half-life)
44 NAS MMT vs. BMT NAS profile differs between methadone (MMT) and buprenorphine (BMT) MMT had greater severity for 5 NAS signs Central nervous system hyperirritability (e.g. hyperactive Moro reflex, tremors, excessive irritability) and failure to thrive Nasal stuffiness, sneezing & loose stools more often with BMT
45 NAS MMT vs. BMT (2) Onset of symptoms around hours, with late presentations up to 5-7 days, peaks within hours Difference in median time to initiation of treatment: 36 hours for MMT and 59 hours for BMT associated with differences in pharmacokinetics & transplacental transfer
46 NAS Nonpharmacologic Measures Supportive interventions for all opioid-exposed infants o Support for mother-baby dyad (e.g., rooming in) o Self-soothing behaviors: non-nutritive sucking, swaddling to decrease arousals & prolong sleep o Cuddling, gentle handling, skin to skin contact and infant slings improve behavioural adaptation of infants with NAS
47 NAS Nonpharmacologic Measures (2) o Environmental modification to reduce sensory stimulation (eg. minimize overhead lighting, reduce noise) o Proper positioning, use of gentle firm pressure and gentle vertical rocking can support neonatal selfregulation o Frequent, smaller volume, hypercaloric feeds
48 NAS Pharmacotherapy Pharmacotherapy should be considered for treatment of NAS when supportive measures fail to adequately ameliorate signs of withdrawal and score reaches threshold for treatment Baby should be admitted to special care nursery or pediatric unit if pharmacologic treatment is indicated to allow for cardiorespiratory monitoring. Treatment indicated in up to 40-50%
49 NAS Pharmacotherapy (2) 2 strategies for NAS treatment: 1. Weight-based: medication dose is based on infant s weight (mg/kg basis) 2. Symptom-based: dose is independent of infant s weight, based on NAS score Protocols vary in initial dose, dose increments, weaning dose and initiation of additional treatment
50 NAS Pharmacotherapy (3) Opioids (e.g. morphine) recommended as first-line agents for treatment of NAS Studies have documents benefits of opioids: reduce time to regain birth weight decrease incidence of severe NAS reduce duration of treatment and rate of admission to nursery Morphine is most commonly used
51 NAS Opioids Morphine preparations include: Diluted tincture of opium Preservative-free morphine solution (no alcohol/additives) Methadone is an alternative to morphine: used infrequently Buprenorphine has been shown in preliminary reports as a safe alternative treatment for NAS
52 NAS Adjunctive Treatment Clonidine Clonidine: central alpha2-adrenergic receptor reduces sympathetic outflow (eg. helps to treat tachycardia, hypertension, restlessness and diarrhea) Demonstrated effective second-line agent as an adjunct to high dose morphine to control withdrawal symptoms addition of clonidine to morphine shortens length of treatment by ~30%
53 NAS Adjunctive Treatment Phenobarbital Phenobarbital: long-acting barbiturate Indications for use: maternal polysubstance use combination of opioids with sedatives, alcohol or barbiturates Demonstrated third-line agent to reduce withdrawal severity Clonidine compared to phenobarbital showed that clonidine was associated with shorter duration of NAS treatment
54 NAS Pharmacotherapy Weaning Weaning off pharmacotherapy occurs once neonatal withdrawal symptoms stabilize occurs in inpatient setting Scoring to continue for additional hours after pharmacologic therapy has been discontinued
55 NAS Effect of Breastfeeding Methadone and buprenorphine detected in breast milk Methadone found in low concentrations Earlier studies documented that breastfed infants had lower NAS scores, lower treatment rates and shorter length of stay compared to those who are formula-fed or combination-fed More recent study confirmed trend of reduced severity and duration of NAS in breastfed methadoneexposed infants
56 NAS Effect of Breastfeeding (2) Concentration of buprenorphine in breast milk low, but due to its poor oral bioavailability, infants receive <1% of maternal weight-adjusted dose Recent study results indicated that although 70% of mothers were breastfeeding, 35% of infants required treatment for NAS; not significant difference Another study found breastfeeding buprenorphineexposed infants had lower treatment rates and shorter length of stay
57 Resources Neonatal Abstinence Working Group Convened by the Ontario Provincial Council for Maternal and Child Health (PCMCH) Goal: to address management of NAS resulting from use of opioids Outcome: developed recommendations during preconception, antenatal and postpartum stages based on research evidence and consensus
58 Future Areas of Research Determining different pathways in opioid withdrawal Optimal assessment tool for NAS Optimal protocol for NAS management (ie. weight- vs. symptom-based) Optimal medication for management of NAS Family-integrated neonatal care models
59 Thank you Any questions?
60 References Finnegan L. (2013). Substance abuse in Canada: licit and illicit drug use during pregnancy: Maternal, neonatal and early childhood consequences. Ottawa: ON: Canadian Centre on Substance Abuse. Wong S, Ordean A, Kahan M. Substance use in pregnancy. JOGC. 2011; 33(4): Ordean A, Kahan M. Comprehensive treatment program for pregnant substance users in a family medicine clinic. Canadian Family Physician 2011; 57: e Exposure to Psychotropic Medications and Other Substances During Pregnancy and Breastfeeding: A Handbook for Health Care Providers. Free from CAMH.
61 References (2) Jones HE, Kaltenbach K, Heil SH, Stine SM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. NEJM. 2010; 363(24): Ordean A, Chisamore BC. Clinical presentation and management of neonatal abstinence syndrome: an update. Research and Reports in Neonatology 2014; 4: World Health Organization.Guidelines for the identification and management of substance use and substance use disorders in pregnancy
Neonatal Abstinence Syndrome: Indian Health Service (IHS) Best Practices Guidelines
Neonatal Abstinence Syndrome: Indian Health Service (IHS) Best Practices Guidelines 1. Neonatal Drug Withdrawal Intrauterine exposure to certain drugs and medications can cause clinical symptoms in the
More informationCurrent Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010
Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010 Substance Exposed Newborns Alcohol Tobacco Caffeine Amphetamines Cocaine Barbituates Selective Serotonin Re-uptake
More informationIdentifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines University of Iowa Children s Hospital -2/11/13
Identifying Neonatal Abstinence Syndrome (NAS) and Treatment Guidelines University of Iowa Children s Hospital -// What is Neonatal Abstinence Syndrome? Neonatal withdrawal after intrauterine exposure
More informationMANAGEMENT OF PERINATAL PRESCRIPTION OPIOID USE LEARNING OBJECTIVES SUBSTANCE USE DISORDER 04/03/2014
MANAGEMENT OF PERINATAL PRESCRIPTION OPIOID USE Alice Ordean MD, CCFP, MHSc, FCFP Medical Director, T CUP, St. Joseph s Health Centre, Toronto Assistant Professor, Department of Family & Community Medicine,
More informationNEONATAL ABSTINENCE SYNDROME. Osama Naga, M.D. PGY2
NEONATAL ABSTINENCE SYNDROME Osama Naga, M.D. PGY2 Objective: Describe the common causes of NAS Clinical Presentation Diagnosis Identify the different scoring system for pharmacologic therapy Minimize
More informationSubstance Abuse lifestyle Concern for mother - fetus - and - neonate
OBJECTIVES Learn about types of opioids and associated withdrawal symptoms Learn what medications are available to treat opioid addiction Understand the pros and cons associated with each medication Understand
More informationNEONATAL ABSTINENCE SYNDROME AND SCORING SYSTEM
VIDANT MEDICAL CENTER PATIENT CARE _ SUBJECT: Abstinence Scoring NUMBER: A-1 PAGE: 1 OF: 5 _ NEONATAL ABSTINENCE SYNDROME AND SCORING SYSTEM POLICY: A thorough evaluation of the infant is required in order
More informationWhat is Methadone? Opioid Treatment Programs Today. Is Methadone Safe? Pain Clinics. Wisconsin OTPs. Methadone Maintenance Treatment 5/6/2013
Methadone Maintenance Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority April 22, 2013 What is Methadone? Schedule II pharmaceutical opioid similar to Oxycodone or morphine. Binds to the
More informationIntroduction to Neonatal Abstinence Syndrome
Introduction to Neonatal Abstinence Syndrome Cara Christ, MD Director, Arizona Department of Health Services Learning Objectives 1.Define Neonatal Abstinence Syndrome 2.Describe Neonatal Abstinence Syndrome
More informationSubstance Abuse During Pregnancy: Moms on Meds. Jennifer Anderson Maddron, M.D LeConte Womens Healthcare Associates
Substance Abuse During Pregnancy: Moms on Meds Jennifer Anderson Maddron, M.D LeConte Womens Healthcare Associates 2010 National Survey on Drug Use and Health An estimated 4.4% of pregnant women reported
More informationWelcome. How Do I Ask Questions? Agenda. Thank you for joining us today. The webinar will begin in a few moments.
Welcome How Do I Ask Questions? Thank you for joining us today. The webinar will begin in a few moments. If you are experiencing technical problems with the GoToWebinar program, contact the GoToWebinar
More informationPregnancy and Opiate Dependence
Making the Switch Opioid Dependence in Pregnancy Alice Ordean, MD, CCFP; and Meldon Kahan, MD, CCFP, FCFP, FRCPC Originally scheduled for presentation at the University of Toronto s Primary Care Today
More informationManagement of Pregnancy. Opioid Addiction Treatment
Management of Pregnancy Opioid Addiction Treatment Perinatal Opioid Addiction Pharmacotherapy and co-ordination of care are essential elements in the comprehensive care of pregnant patients with opioid
More information(peak at 2 days 6 wks)
Perinatal Manual of Southwestern Ontario A collaboration between the Regional Perinatal Outreach Program of Southwestern Ontario & the Southwestern Ontario Perinatal Partnership (SWOPP) Chapter 46 NEONATAL
More informationManagement of Neonatal Abstinence Syndrome and Iatrogenic Drug Withdrawal
Management of Neonatal Abstinence Syndrome and Iatrogenic Drug Withdrawal Kirsten H. Ohler, Pharm.D., BCPS Clinical Assistant Professor Neonatal / Pediatric Clinical Pharmacist University of Illinois at
More informationSUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011
INTRODUCTION SUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011 Prevalence of Opiate Use and Impact on Maternal, Fetal, and Neonatal Health: The prevalence of
More informationCHILDREN S SERVICES. Neonatal Abstinence Syndrome
CHILDREN S SERVICES Neonatal Abstinence Syndrome Background Neonatal Abstinence Syndrome (NAS) is a combination of behavioural and physiological signs and symptoms that occur in newborns going through
More informationMagee-Womens Hospital
Magee-Womens Hospital Magee Pregnancy Recovery Program: History Pregnancy Recovery Center A Medical Home Model Approach to Strengthen Families Bawn Maguire, MSN, RN Programmatic Nurse Specialist Stephanie
More informationOpioid/Opiate Dependent Pregnant Women
Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than
More informationSubstance Use Guideline 4B PERINATAL OPIOID EXPOSURE, CARE OF THE NEWBORN
British Columbia Reproductive Care Program Substance Use Guideline 4B PERINATAL OPIOID EXPOSURE, CARE OF THE NEWBORN INTRODUCTION During the antenatal period, the opportunity exists for the primary care
More informationMethadone and Pregnancy
Methadone and Pregnancy Methadone 101/Hospitalist Workshop Launette Rieb, MD, MSc, CCFP, CCSAM, FCFP Clinical Associate Professor, Dept. Family Practice, UBC American Board of Addiction Medicine Certified
More informationPresentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas
Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas David Lakey, MD Commissioner, Department of State Health Services Lauren Lacefield Lewis Assistant Commissioner,
More informationIdentifying and Managing Substance Use During Pregnancy
Identifying and Managing Substance Use During Pregnancy Joseph B. Landwehr, Jr., MD Director, Perinatal Center IU Health Ball Memorial Hospital OBJECTIVES Overview of illicit drug use in pregnant women
More informationHeroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
More informationSubstitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015
Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid
More informationHeroin. How Is Heroin Abused? How Does Heroin Affect the Brain? What Other Adverse Effects Does Heroin Have on Health?
Heroin Heroin is an opiate drug that is synthesized from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears as a white or brown
More informationHeroin. How is Heroin Abused? What Other Adverse Effects Does Heroin Have on Health? How Does Heroin Affect the Brain?
Heroin Heroin is a synthetic opiate drug that is highly addictive. It is made from morphine, a naturally occurring substance extracted from the seed pod of the Asian opium poppy plant. Heroin usually appears
More informationNNEPQIN Guideline for the Management of Labor, Delivery and the Newborn in the Opioid Dependent Pregnancy. March 2014
The following guidelines are intended only as a general educational resource for hospitals and clinicians, and are not intended to reflect or establish a standard of care or to replace individual clinician
More informationOpiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,
More informationFrom the street to the NICU. Richard Christensen, PA, CAS
From the street to the NICU Richard Christensen, PA, CAS Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a stand-alone
More informationMedication Assisted Treatment
Medication Assisted Treatment Tanya Hiser, MS, LPC State Opioid Treatment Authority Bureau Of Prevention, Treatment, & Recovery State of Wisconsin Elizabeth Collier, MSW, CSAC, ICS, LCSW TANF Best Practice
More informationConsiderations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT
Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA
More informationFDA Presentation: Maternal Perspective on Opioid Medication Assisted Therapy
FDA Presentation: Maternal Perspective on Opioid Medication Assisted Therapy Lorraine A. Milio, M.D. Obstetrical Director Center for Addiction and Pregnancy Assistant Professor Maternal-Fetal Medicine
More informationCare Management Council submission date: August 2013. Contact Information
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing
More informationCollaborative Care for Pregnant Women with Substance Use Disorders
Collaborative Care for Pregnant Women with Substance Use Disorders Alane O Connor DNP Maine Dartmouth Family Medicine Residency MaineGeneral Medical Center Dartmouth Medical School Vanderbilt University
More informationTreatment Guidelines for Neonatal Narcotic Abstinence Syndrome with Diluted Oral Morphine and Clonidine
Treatment Guidelines for Neonatal Narcotic Abstinence Syndrome with Diluted Oral Morphine and Clonidine Background Morphine sulfate has been recommended by the AAP as the first-line agent for the pharmacologic
More informationJohn R. Kasich, Governor Orman Hall, Director
John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemic
More informationEstablished in 1974 Non-Profit Federal Block Grant recipient Accept Medicaid, Private Insurance, and Self-Pay.
Established in 1974 Non-Profit Federal Block Grant recipient Accept Medicaid, Private Insurance, and Self-Pay. Patients are not denied treatment if they do not have the ability to pay for services Schedule
More informationThe Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
More informationEPIDEMIOLOGY OF OPIATE USE
Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months
More informationUpdate on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
More informationOpioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist
Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids
More informationOffice-based Treatment of Opioid Dependence with Buprenorphine
Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures
More informationNeonatal Abstinence Syndrome
Neonatal Abstinence Syndrome D COGHLAN, *M MILNER, T CLARKE, I LAMBERT, C MCDERMOT, M MCNALLY, M BECKETT. T MATTHEWS Department of Paediatrics and *Obstetrics. Rotunda Hospital. Parnell Square. Dublin
More informationV11.2 NPIC/QAS. Special Quarterly Report: Linked Analysis Neonatal Abstinence Syndrome
V11.2 NPIC/QAS Special Quarterly Report: Linked Analysis Neonatal Abstinence Syndrome I. Background The use of drugs and alcohol during pregnancy has been shown in several studies to affect the health
More informationUse of Buprenorphine in the Treatment of Opioid Addiction
Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an
More informationUnderstanding Medication Assisted Treatment (MAT) for Families Affected by Substance Use Disorders
Understanding Medication Assisted Treatment (MAT) for Families Affected by Substance Use Disorders March 20, 2013 Pamela Petersen- Baston, MPA, CAP, CPP 4 9 4 0 I r v i n e B l v d., S u i t e 2 0 2 I
More informationMedication is not a part of treatment.
Medication is not a part of treatment. Medication can be an effective part of treatment. Medication is used in the treatment of many diseases, including addiction. Medical decisions must be made by trained
More informationTENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION
TENNESSEE BOARD OF MEDICAL EXAMINERS POLICY STATEMENT OFFICE-BASED TREATMENT OF OPIOID ADDICTION The Tennessee Board of Medical Examiners has reviewed the Model Policy Guidelines for Opioid Addiction Treatment
More informationAbstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
More informationPregnancy and Addiction: A World View of the Problem, Current Treatments and Future Research
Pregnancy and Addiction: A World View of the Problem, Current Treatments and Future Research Hendree E. Jones Associate Professor, Department of Psychiatry Johns Hopkins University Outline I. World view
More informationPrescription Drug Addiction
Prescription Drug Addiction Dr Gilbert Whitton FAChAM Clinical Director Drug & Alcohol Loddon Mallee Murray Medicare Local Deniliquin 14 th May 2014 Prescription Drug Addiction Overview History Benzodiazepines
More informationGuidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Patients with a substance misuse history are at increased risk of receiving inadequate
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationJoel Millard, DSW, LCSW Dave Felt, LCSW
Joel Millard, DSW, LCSW Dave Felt, LCSW 1. Provide an overview of the effectiveness of medication assisted treatment, to include a discussion of the different types of medications and how they are used
More informationOVERVIEW OF MEDICATION ASSISTED TREATMENT
Sarah Akerman MD Assistant Professor of Psychiatry Director of Addiction Services Geisel School of Medicine/Dartmouth-Hitchcock Medical Center OVERVIEW OF MEDICATION ASSISTED TREATMENT Conflicts of Interest
More informationWales Neonatal Network Guideline
Guideline on the Management of Neonatal Abstinence Syndrome Introduction Neonatal Abstinence Syndrome (NAS) is a constellation of symptoms and signs occurring in a baby as a result of withdrawal from physically
More informationEPIDEMIC 4.6 % OF INDIVIDUALS 18 25 USED PAIN RELIEVERS FOR NON-MEDICAL REASONS. 1.5 MILLION YOUNG ADULTS USED PAIN RELIEVERS IN THE PAST MONTH.
Drug Court EPIDEMIC In the 10 years (1997 2007) the per capita retail purchases of Methadone, Hydrocodone and Oxycodone in the United States increased 13-fold, 4-fold and 9-fold, respectively. 4.6 % OF
More informationBABIES BORN TO ADDICTED MOTHERS
BABIES BORN TO ADDICTED MOTHERS PATRICA M. MESSERLE LICENSED CLINICAL PSYCHOLOGIST, M.A., ABSNP LICENSED SCHOOL PSYCHOLOGIST DIPLOMATE OF THE AMERICAN BOARD OF SCHOOL- NEUROPSYCHOLOGY 1 Signs and Symptoms
More informationAddressing Substance Use in Pregnancy
Addressing Substance Use in Pregnancy Stefan Maxwell, MD Director, NICU, CAMC Women and Children s Hospital Chair, Drug Use in Pregnancy Committee West Virginia Perinatal Partnership July 31, 2013 WV Early
More information3/31/2015. Objectives. Alcohol. Long term effects. Substance abuse increases the risk of: Substance Abuse in Pregnancy
Objectives Substance Abuse in Pregnancy Basics of screening and counseling Minako Watabe, MD Obstetrics and Gynecology Ventura County Medical Center 1) Discuss the risks of alcohol, tobacco, and drug use
More informationBuprenorphine: what is it & why use it?
Buprenorphine: what is it & why use it? Dr Nicholas Lintzeris, MBBS, PhD, FAChAM Locum Consultant, Oaks Resource Centre, SLAM National Addiction Centre, Institute of Psychiatry Overview of presentation
More informationMEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
More informationInformation for Pharmacists
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
More informationHow To Treat A Drug Addiction
1 About drugs Drugs are substances that change a person s physical or mental state. The vast majority of drugs are used to treat medical conditions, both physical and mental. Some, however, are used outside
More informationTreatment of opioid use disorders
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
More informationSection Editor Andrew J Saxon, MD
Official reprint from UpToDate www.uptodate.com 2015 UpToDate Pharmacotherapy for opioid use disorder Author Eric Strain, MD Section Editor Andrew J Saxon, MD Deputy Editor Richard Hermann, MD All topics
More informationHow To Treat Anorexic Addiction With Medication Assisted Treatment
Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious
More informationUsing Buprenorphine to Treat Acute Opioid Withdrawal in the ED
Using Buprenorphine to Treat Acute Opioid Withdrawal in the ED Dr. Karine Meador MD CCFP DABAM Assistant Director Inner City Health and Wellness Team Physician Addiction Recovery and Community Health (ARCH)
More informationTreatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective
Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions for
More informationmethadonefact.qxd 8/11/01 2:05 PM Page 1 INFORMATION Advantages of methadone treatment DEPRESSANT Methadone maintenance Pregnancy METHADONE
methadonefact.qxd 8/11/01 2:05 PM Page 1 INFORMATION Advantages of methadone treatment 10 DEPRESSANT Methadone maintenance Pregnancy METHADONE methadonefact.qxd 8/11/01 2:05 PM Page 2 WHAT IS METHADONE
More informationTreatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy
Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,
More informationUnderstanding Addiction: The Intersection of Biology and Psychology
Understanding Addiction: The Intersection of Biology and Psychology Robert Heimer, Ph.D. Yale University School of Public Health Center for Interdisciplinary Research on AIDS New Haven, CT, USA November
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
More informationTreatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )
Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate
More informationPregnancy and Substance Abuse
Pregnancy and Substance Abuse Introduction When you are pregnant, you are not just "eating for two." You also breathe and drink for two, so it is important to carefully consider what you put into your
More informationNew York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery
New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery USING THE 48 HOUR OBSERVATION BED USING THE 48 HOUR OBSERVATION BED Detoxification
More informationKarol Kaltenbach, PhD Maternal Addiction Treatment Education and. Jefferson Medical College Thomas Jefferson University
Benzodiazepines and the Pregnant Patient: Special Challenges Karol Kaltenbach, PhD Maternal Addiction Treatment Education and Research Jefferson Medical College Thomas Jefferson University Outline Introduction
More information1. According to recent US national estimates, which of the following substances is associated
1 Chapter 36. Substance-Related, Self-Assessment Questions 1. According to recent US national estimates, which of the following substances is associated with the highest incidence of new drug initiates
More informationThe CCB Science 2 Service Distance Learning Program
S2S 2055 DETOXIFICATION Module 1 Post-Test 1. A common use of a biochemical marker is. a. to support or refute other information that leads to proper diagnosis b. for forensic purposes c. in detecting
More informationLike cocaine, heroin is a drug that is illegal in some areas of the world. Heroin is highly addictive.
Heroin Introduction Heroin is a powerful drug that affects the brain. People who use it can form a strong addiction. Addiction is when a drug user can t stop taking a drug, even when he or she wants to.
More informationMedication treatments for opioid use disorders
Medication treatments for opioid use disorders Summary for counties JUDITH MARTIN, Medical Director of Substance Use Services, San Francisco Department of Public Health Brief history of Methadone and Buprenorphine
More informationThe Clinical Content of Preconception Care: Alcohol, Tobacco, and Illicit Drug Exposures
The Clinical Content of Preconception Care: Alcohol, Tobacco, and Illicit Drug Exposures by R. Louise Floyd, DSN, RN; Brian W. Jack, MD; Robert Cefalo, MD, PhD; Hani Atrash, MD, MPH; Jeanne Mahoney, BSN,
More information10/19/15. Stephen Loyd, M.D., F.A.C.P Healthy Kingsport Meadowview Convention Center Kingsport, Tennessee October 17, 2015
Stephen Loyd, M.D., F.A.C.P Healthy Kingsport Meadowview Convention Center Kingsport, Tennessee October 17, 2015 Receives no commercial support, in any form, from pharmaceutical companies or anyone else
More informationOne example: Chapman and Huygens, 1988, British Journal of Addiction
This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman
More informationNEONATAL ABSTINENCE SYNDROME (NAS)- THE CARE YOUR BABY MAY NEED
NEONATAL ABSTINENCE SYNDROME (NAS)- THE CARE YOUR BABY MAY NEED Information Leaflet Your Health. Our Priority. Page 2 of 8 Welcome to Stepping Hill Hospital Women's Unit The aims of this leaflet are to:
More informationCompassionate Care In Treating Opioid Dependence During Pregnancy
Compassionate Care In Treating Opioid Dependence During Pregnancy Michelle Lofwall, M.D. University of Kentucky College of Medicine Depts. of Behavioral Science and Psychiatry April 26, 2014 1 None Faculty
More informationMEDICATION-ASSISTED DRUG TREATMENT AND CHILD WELL-BEING
MEDICATION-ASSISTED DRUG TREATMENT AND CHILD WELL-BEING Lena Lundgren, Ph.D.¹ Nancy K. Young, P.h.D.² Therese Fitzgerald, M.S.W.¹ Cat Oettinger, B.A. ¹ ¹ Center on Work and Family, Boston University ²
More informationST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15
ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;/13;06/14;07/15 WRITTEN BY Jim Johnson Page 1 REVISED BY AUTHORIZED BY Jessica Moeller Debra Johnson I. APPLICATION: THUMB
More informationEvaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients
Evaluation of a Morphine Weaning Protocol in Pediatric Intensive Care Patients Jennifer Kuhns, Pharm.D. Pharmacy Practice Resident Children s Hospital of Michigan **The speaker has no actual or potential
More informationProgram Assistance Letter
Program Assistance Letter DOCUMENT NUMBER: 2004-01 DATE: December 5, 2003 DOCUMENT TITLE: Use of Buprenorphine in Health Center Substance Abuse Treatment Programs TO: All Bureau of Primary Health Care
More informationEthical Issues Related to Long-Term Consequences of Neonatal Abstinence Syndrome (NAS) Christopher Church, Ph.D.
Ethical Issues Related to Long-Term Consequences of Neonatal Abstinence Syndrome (NAS) Christopher Church, Ph.D. Content and Objectives Content: Describe common ethical issues related to caring for babies
More informationMedication-Assisted Addiction Treatment
Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling
More informationOPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School
OPIOIDS Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School Rutgers New Jersey Medical School Fundamentals of Addiction Medicine Summer Series Newark, NJ July 24, 2013
More informationSOUTH CENTRAL NEONATAL NETWORK GUIDELINE. South Central (North) Guideline for Neonatal Drug Withdrawal
SOUTH CENTRAL NEONATAL NETWORK GUIDELINE South Central (North) Guideline for Neonatal Drug Withdrawal Approved by & South Central Neonatal Steering Group for South Central North. date Date of Implementation
More informationOutline Substance Abuse Screening in Pregnancy
Outline Substance Abuse Screening in Pregnancy Allison S. Bryant, MD, MPH Department of Obstetrics, Gynecology & RS University of California, San Francisco Antepartum and Intrapartum Management June 7,
More informationNeonatal Abstinence Syndrome (NAS)
Women and Newborn Health Service King Edward Memorial Hospital Neonatal Abstinence Syndrome (NAS) W O M E N A N D N E W B O R N drug and alcohol service (wandas) Delivering a Healthy WA Neonatal Abstinence
More informationDeath in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
More informationOpioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
More informationOpioids Information for Health Professionals
Opioids Information for Health Professionals Introduction Opioid is the generic term for any substance that binds to the opioid receptors found in the central nervous system (CNS), gastrointestinal tract,
More information